This is a multicenter, single-arm, open-label, phase 2 Window-of-opportunity trial to assess the activity of 1 cycle of preoperative retifanlimab plus platinum-etoposide chemo-immunotherapy regimen in patients with resectable MCC (stage IIA-III).~Patients who meet the eligibility criteria will be treated with one cycle of chemo-immunotherapy.~After receiving the short-course preoperative chemo-immunotherapy study regimen, patients will undergo standard radical surgery between weeks 5 and 6 from enrollment. After surgery, patients will receive adjuvant radiation therapy, if indicated, and afterwards, standard follow up will be started as per clinical practice and guidelines.~Baseline radiological assessments will include chest/abdomen/pelvis CT scan with contrast and CT scan of additional anatomical sites should be performed if the primary tumor is elsewhere.~The enrollment of patients will be temporary interrupted after the inclusion of first 6 patients in the trial. When 6 patients will complete the study treatment, a Safety Monitoring Committee will complete a safety evaluation.~The enrollment will then resume only if the study treatment combination is judged feasible and no major safety concerns arise.~The study primary endpoint will be the pathological complete response rate or pCR rate, defined as the percentage of patients, relative to the total of enrolled subjects in the intention-to-treat population, who will achieve a pathological complete response, as per central pathological review.
This is a window-of-opportunity study for patients with resectable Merkel Cell Carcinoma.~The aim of this study is to test the activity of a course of chemo-immunotherapy followed by surgery in patients with operable Merkel cell carcinoma.~Participants will receive one cycle of retifanlimab plus platinum-etoposide chemotherapy prior to their scheduled surgery.